ASCO 2019 Annual Meeting

June 01 - 03 

McCormick Place, Chicago

Booth: #20005

Stop by Booth 20005 to learn more about these Roche solutions and more

AVENIO NGS Assays for Clinical Research

AVENIO family of NGS oncology assays for plasma and FFPE tumor tissue provide a dynamic, comprehensive genomic profile of solid tumors through the analysis of both ctDNA and FFPE tumor tissue.

For Research Use Only. Not for Use in Diagnostic Procedures.

Learn How

NAVIFY® Tumor Board

A cloud-based workflow product that securely integrates and displays relevant aggregated data into a single, holistic patient dashboard for oncology care teams to review, align and decide on the optimal treatment for the patient.

Learn More

NAVIFY® Mutation Profiler*

A clinical NGS reporting solution that can help labs accurately and efficiently interpret the clinical significance of mutations, empowering clinicians to deliver more personalized healthcare.

*Not yet commercially available in the US

cobas® EGFR Mutation Test v2

The only FDA-approved diagnostic test for NSCLC using liquid biopsy.

Companion diagnostic for Tarceva® (erlotinib), IRESSA® (gefitinib), and TAGRISSO® (osimertinib)

Learn More

Come listen to our Tumor Board Symposium on June 1st @6:30pm

Multidisciplinary Management of Complex Lung Cancer in the Era of Precision Oncology

June 1, 6:30-8:00 pm, Marriott Marquis Chicago

Register Here

AVENIO is for Research Use Only. Not for use in diagnostic procedures. 
AVENIO, COBAS and NAVIFY are a trademarks of Roche. All other product names and trademarks are the property of their respective owners.